WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)

Charité University Medicine Berlin logo

Charité University Medicine Berlin

Status and phase

Unknown
Phase 2

Conditions

Myelodysplastic Syndrome
Acute Myeloid Leukemia

Treatments

Biological: WT1 126-134 peptide

Study type

Interventional

Funder types

Other

Identifiers

NCT00153582
Carreras 04/25f
HaemaCBFWT102

Details and patient eligibility

About

In this trial, HLA-A2+ patients with active AML are vaccinated with a peptide from the leukemia-associated antigen WT1 together with immunological adjuvants keyhole limpet hemocyanin (KLH) as T-helper protein and granulocyte macrophage colony stimulating factor (GM-CSF) 4 times bi-weekly, then monthly.

Full description

In this phase II trial HLA-A2+ patients with active AML without curative treatment option are vaccinated with WT1 126-134 peptide mixed with adjuvant KLH as T-helper protein and GM-CSF 4 times bi-weekly, then monthly.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • AML or myelodysplastic syndromes (MDS)
  • Partial response (PR) or complete response (CR) or smoldering course without option for allogeneic stem cell transplantation
  • HLA-A2+
  • WT1-expression in bone marrow

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Central trial contact

Carmen Scheibenbogen, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems